Turning ETEC Vaccine Development into Real Impact – Together with EDCTP

Developing a vaccine against ETEC in young children has long been a global health challenge. We are now closer than ever to changing that. At Scandinavian Biopharma, we are advancing what could become the world’s first vaccine to protect young children against ETEC—a major cause of diarrhoeal disease affecting millions globally. The progress highlighted by EDCTP […]

ETVAX Gains Attention as Hope Rises Against Childhood Diarrhoea

Scientific American has highlighted ETVAX, our oral vaccine candidate targeting enterotoxigenic E. coli (ETEC) — one of the leading causes of severe diarrhoea in young children in low- and middle-income countries. The coverage follows the recent publication of our Phase 2b results in The Lancet Infectious Diseases and reflects growing recognition of the urgent need […]